(SEPN) Septerna, Common Stock - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.215m USD | Total Return: 199.2% in 12m
Avg Turnover: 7.72M
Qual. Beats: 0
Rev. Trend: 98.4%
Warnings
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' 0.45 < 1.0 - financial distress zone
Fakeout Choppy
Tailwinds
Leader
Septerna, Inc. (SEPN) is a clinical-stage biotechnology firm specializing in the discovery and development of oral small molecule therapies targeting G protein-coupled receptors (GPCRs). The company’s pipeline addresses endocrine, metabolic, and inflammatory disorders, with primary candidates including a PTH1R agonist for hypoparathyroidism and SEP-631 for chronic spontaneous urticaria. GPCRs represent one of the largest classes of drug targets, though many remain difficult to address with traditional oral chemistries.
The company operates through a collaborative business model, leveraging its Native GPCR Discovery Platform to secure strategic partnerships. Notably, Septerna maintains a global licensing agreement with Novo Nordisk to develop therapies for metabolic diseases. For a deeper look at the fundamental metrics driving this stock, you may find further analysis on ValueRay helpful.
Headquartered in South San Francisco, Septerna focuses on expanding its platform into neurology, cardiovascular disease, and women’s health. By prioritizing oral small molecules over injectable biologics, the company aims to improve patient compliance and reduce delivery costs within the pharmaceutical sector.
- Clinical data readouts for PTH1R program drive near-term valuation and investor sentiment
- Novo Nordisk collaboration milestones provide non-dilutive capital and validation of GPCR platform
- Progress of SEP-631 through early trials impacts long-term immunology and inflammation pipeline
- High research and development expenditures necessitate future capital raises and equity dilution
- Regulatory approval hurdles for oral small molecule alternatives to existing injectable therapies
| Net Income: -36.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 36.24 > 1.0 |
| NWC/Revenue: 401.2% < 20% (prev 34.0k%; Δ -33.6k% < -1%) |
| CFO/TA 0.19 > 3% & CFO 107.9m > Net Income -36.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.8m) vs 12m ago 1.87% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 14.40% > 50% (prev 0.23%; Δ 14.17% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.51 (Total Current Assets 368.1m - Total Current Liabilities 78.2m) / Total Assets 569.7m |
| B: -0.31 (Retained Earnings -175.9m / Total Assets 569.7m) |
| C: -0.14 (EBIT TTM -68.2m / Avg Total Assets 501.9m) |
| D: -0.92 (Book Value of Equity -176.4m / Total Liabilities 191.2m) |
| Altman-Z'' = 0.45 = B |
| DSRI: 0.11 (Receivables 10.8m/1.33m, Revenue 72.3m/977k) |
| GMI: 1.02 (GM 97.78% / 100.0%) |
| AQI: 2.12 (AQ_t 0.31 / AQ_t-1 0.15) |
| SGI: 73.96 (Revenue 72.3m / 977k) |
| TATA: -0.25 (NI -36.0m - CFO 107.9m) / TA 569.7m) |
| Beneish M = 48.98 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 27.92 with a total of 232,415 shares traded.
Over the past week, the price has changed by +5.23%,
over one month by +9.67%,
over three months by +1.29% and
over the past year by +199.16%.
Septerna, Common Stock has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SEPN.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.3 | 58.5% |
P/S = 16.8125
P/B = 2.8093
Revenue TTM = 72.3m USD
EBIT TTM = -68.2m USD
EBITDA TTM = -66.6m USD
Long Term Debt = 20.8m USD (estimated: total debt 23.1m - short term 2.31m)
Short Term Debt = 2.31m USD (from shortTermDebt, last quarter)
Debt = 23.1m USD (from shortLongTermDebtTotal, last quarter) (leases 23.6m already included)
Net Debt = -324.3m USD (calculated: Debt 23.1m - CCE 347.4m)
Enterprise Value = 890.5m USD (1.21b + Debt 23.1m - CCE 347.4m)
Interest Coverage Ratio = unknown (Ebit TTM -68.2m / Interest Expense TTM 0.0)
EV/FCF = 8.33x (Enterprise Value 890.5m / FCF TTM 106.9m)
FCF Yield = 12.01% (FCF TTM 106.9m / Enterprise Value 890.5m)
FCF Margin = 148.0% (FCF TTM 106.9m / Revenue TTM 72.3m)
Net Margin = -49.88% (Net Income TTM -36.0m / Revenue TTM 72.3m)
Gross Margin = unknown ((Revenue TTM 72.3m - Cost of Revenue TTM 1.60m) / Revenue TTM)
Tobins Q-Ratio = 1.56 (Enterprise Value 890.5m / Total Assets 569.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 23.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -53.9m (EBIT -68.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.71 (Total Current Assets 368.1m / Total Current Liabilities 78.2m)
Debt / Equity = 0.06 (Debt 23.1m / totalStockholderEquity, last quarter 378.5m)
Debt / EBITDA = 4.87 (negative EBITDA) (Net Debt -324.3m / EBITDA -66.6m)
Debt / FCF = -3.03 (Net Debt -324.3m / FCF TTM 106.9m)
Total Stockholder Equity = 381.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.18% (Net Income -36.0m / Total Assets 569.7m)
RoE = -6.46% (Net Income TTM -36.0m / Total Stockholder Equity 557.6m)
RoCE = -11.79% (EBIT -68.2m / Capital Employed (Equity 557.6m + L.T.Debt 20.8m))
RoIC = -10.95% (negative operating profit) (NOPAT -53.9m / Invested Capital 491.8m)
WACC = 11.92% (E(1.21b)/V(1.24b) * Re(12.15%) + D(23.1m)/V(1.24b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.61 | Cagr: 53.83%
[DCF] Terminal Value 64.00% ; FCFF base≈106.9m ; Y1≈107.4m ; Y5≈113.7m
[DCF] Fair Price = 31.61 (EV 1.10b - Net Debt -324.3m = Equity 1.43b / Shares 45.1m; r=11.92% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.10 | # QB: 0
Revenue Correlation: 98.40 | Revenue CAGR: 1.64k% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.42 | Chg30d=-141.54% | Revisions=-33% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.48 | Chg30d=-21.71% | Revisions=-33% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.53 | Chg30d=-28.50% | Revisions=+0% | GrowthEPS=-10.5% | GrowthRev=+81.4%
EPS next Year (2027-12-31): EPS=-2.48 | Chg30d=-27.38% | Revisions=-50% | GrowthEPS=-61.6% | GrowthRev=-25.9%
[Analyst] Revisions Ratio: -50%